4-(Dipropylcarbamoyl)butanoic acid | 76197-47-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4-(Dipropylcarbamoyl)butanoic acid
• 英文别名: 5-(dipropylamino)-5-oxopentanoic acid
• CAS: 76197-47-2
• 化学式: C₁₁H₂₁NO₃
• mdl: MFCD01349369
• 分子量: 215.29
• InChiKey: OSFOQQNTRFDYIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2R,3S)-3-amino-4-(3,5-difluorophenyl)-1-[(3-methoxybenzyl)amino]-2-butanol trifluoroacetate 、 4-(Dipropylcarbamoyl)butanoic acid 生成 N1-{(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-N5,N5-dipropylpentanediamide
  参考文献：
  名称：

  Compounds to treat Alzheimer's disease

  摘要：

  本发明提供了公式（X）和公式（X′）的取代胺化合物，可用于治疗阿尔茨海默病和其他类似疾病。

  公开号：

  US07214715B2

文献信息

• Compounds to treat alzheimer's disease
  申请人：——

  公开号：US20020128255A1

  公开（公告）日：2002-09-12

  The present invention is substituted amines of formula (X) 1 and of the formula (X′) 2 useful in treating Alzheimer's disease and other similar diseases.

  本发明提供的公式（X）1和公式（X'）2的取代胺在治疗阿尔茨海默病和其他类似疾病中有用。
• 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives
  申请人：Nozulak Joachim

  公开号：US20130303538A1

  公开（公告）日：2013-11-14

  The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.

  该发明涉及化合物(I)的公式，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其用作药物以及包含它们的药物。
• 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
  申请人：Nozulak Joachim

  公开号：US09067881B2

  公开（公告）日：2015-06-30

  The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.

  该发明涉及公式（I）中取代基的化合物，其中取代基如规范中定义的；以自由形式或盐形式存在；它们的制备，它们作为药物的用途以及包含它们的药物。
• 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010941A1

  公开（公告）日：1980-05-14

  The present invention provides compounds of the general formula:- wherein R is an optionally substituted bridged alicyclic radical or a substituted lower alkyl radical, the substituent being an optionally substituted bridged alicyclic group, an amino, protected amino, lower alkoxy, acyl, lower alkylthio, cyano(lower)alkylthio, arylthio or optionally substituted heterocyclic radical or a carboxy and esterified carboxy group, with the proviso, that when the substituent is a carboxy or esterified carboxy group then the lower alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted or substituted lower alkenyl radical, the substituent being an optionally substituted bridged alicyclic group, an optionally substituted aryl radical or an optionally substituted heterocyclic radical; or a halophenyl radical; or an optionally substituted heterocyclic radical. 'The present invention also provides processes for the preparation of these compounds and pharmaceutical composition containing them. Furthermore, the present invention is concerned with a method of treating cancer which comprises administering these compounds to mammals suffering from cancer.

  本发明提供通式为：- 的化合物。 其中 R 是任选取代的桥式脂环基或取代的低级烷基，取代基是任选取代的桥式脂环基、氨基、保护氨基、低级烷氧基、酰基、低级烷硫基、氰基（低级）烷硫基、芳硫基或任选取代的杂环基或羧基和酯化羧基，但条件是当取代基是羧基或酯化羧基时，低级烷基含有 3 至 6 个碳原子；或未取代或取代的低级烯基，取代基为任选取代的桥式脂环基、任选取代的芳基或任选取代的杂环基；或卤代苯基；或任选取代的杂环基。 '本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺。此外，本发明还涉及一种治疗癌症的方法，该方法包括对患有癌症的哺乳动物施用这些化合物。
• Amino acid analogs as CCK-antagonists
  申请人：Merck & Co., Inc.

  公开号：EP0250148A2

  公开（公告）日：1987-12-23

  Analogs of glutamic acid and related amino acids and pharmaceutically-acceptable salts thereof which antagonize the function of cholecystokinins and gastrin disease states in animals and compositions for and methods of preventing or treating disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.

  谷氨酸和相关氨基酸的类似物及其药学上可接受的盐，可拮抗动物体内胆囊收缩素的功能和胃泌素疾病状态，以及用于预防或治疗哺乳动物，尤其是人类的胃肠道、中枢神经和食欲调节系统疾病的组合物和方法。